Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy

Inclusion Criteria: * Patients with vulvar cancer already enrolled onto Gynecologic Oncology Group (GOG)-0244 who will undergo or have undergone definitive surgery for primary stage I-IV vulvar cancer who will receive a radical vulvectomy or radical local excision with concurrent unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy; * Patients who are going to receive multi-modality therapy (radiation +/- chemotherapy) after undergoing surgery are eligible * Patients who have met the pre-entry requirements * Patients must have signed an approved informed consent and authorization permitting release of personal health information for GOG-0269 and for GOG-0244 * Patients may undergo sentinel node mapping as long as it is followed by a full lymphadenectomy during the same operative event * Serum Albumin level of \>= 3.0 within 14 days of entry * Patients with a GOG performance status of 0, 1, or 2 Exclusion Criteria: * Patients not enrolled onto GOG-0244 * Patients with any prior clinical history of lower extremity lymphedema * Patients who have a history of congestive heart failure, chronic renal disease, or chronic liver disease * Patients with a prior history of chronic lower extremity swelling * Patients with a GOG Performance Grade of 3 or 4 * Patients with a history of other invasive malignancies if that malignancy included a bilateral lymph node procedure (example: bilateral mastectomies and axillary lymphadenectomies) or if their previous cancer tre…